Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer

Journal of Gastroenterology

Volumn 48, Issue 10, 2013, Pages 1171-1179

  Nouso, Kazuhiro ^a,b   Amano, Maho ^c,d   Ito, Yoichi M ^d   Miyahara, Koji ^b   Morimoto, Yuki ^b   Kato, Hironari ^b   Tsutsumi, Koichiro ^b   Tomoda, Takeshi ^b   Yamamoto, Naoki ^b   Nakamura, Shinichiro ^b   Kobayashi, Sayo ^b   Kuwaki, Kenji ^b   Hagihara, Hiroaki ^b   Onishi, Hideki ^a   Miyake, Yasuhiro ^b   Ikeda, Fusao ^a   Shiraha, Hidenori ^b   Takaki, Akinobu ^b   Nakahara, Taku ^e   Nishimura, Shin Ichiro ^c,d   Yamamoto, Kazuhide ^b   more..

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c Graduate School of Life Science   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Ezose Sciences Incorporation   (United States)

Author keywords

Diagnosis; N glycan; Pancreatic cancer

Indexed keywords

GLYCAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH;

ADULT; AGED; FEMALE; HEALTHY VOLUNTEERS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; JAPAN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYSACCHARIDES; PROGNOSIS; ROC CURVE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885038677     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0732-7     Document Type: Article

References (23)

1. Jemal A, Bray F, Center M.M., Ferlay J., Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Cleary SP, Gryfe R, Guindi M., Greig P, Smith L, Mackenzie R., et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004; 198:722-31.
3. Katz MH, Hwang R, Fleming J.B., Evans DB Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin. 2008; 58:111-25.
4. Stathis A, Moore MJ Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010; 7: 163-72.
5. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am. 2002; 16:37-52.
6. Helenius A, Aebi M. Intracellular functions of N-linked glycans. Science. 2001; 291:2364-9.
7. Zhao Y, Sato Y, Isaji T., Fukuda T, Matsumoto A, Miyoshi E., et al. Branched N-glycans regulate the biological functions of integrins and cadherins. FEBS J. 2008; 275:1939-48.
8. Zhao YY, Takahashi M, Gu J.G., Miyoshi E., Matsumoto A, Kit-azume S, et al Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci. 2008; 99:1304-10.
9. Barrabes S, Pages-Pons L, Radcliffe C.M., Tabares G., Fort E, Royle L, et al Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosy-lation in pancreatic cancer. Glycobiology. 2007; 17:388-400.
10. Ide Y, Miyoshi E, Nakagawa T., Gu J, Tanemura M, Nishida T., et al. Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer. Biochem Biophys Res Commun. 2006; 341:478-82.
11. Li C, Simeone DM, Brenner D.E., Anderson MA, Shedden KA, Ruffin MT, et al Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J Proteome Res. 2009; 8:483-92.
12. Li Z, Yamada S, Inenaga S., Imamura T, Wu Y, Wang K.Y., et al. Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer. 2011; 104:1882-9.
13. Lin Z, Simeone DM, Anderson M.A., Brand RE, Xie X, Shedden KA, et al Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. J Proteome Res. 2011; 10: 2602-11.
14. Miyoshi E, Nakano M. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics. 2008; 8:3257-62.
15. Morohashi H, Kon A, Nakai M., Yamaguchi M, Kakizaki I, Yo-shihara S, et al. Study of hyaluronan synthase inhibitor, 4-meth-ylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL). Biochem Biophys Res Commun. 2006; 345:1454-9.
16. Zhao J, Patwa TH, Qiu W, Shedden K., Hinderer R, Misek DE, et al Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J Proteome Res. 2007; 6:1864-74.
17. Zhao J, Qiu W, Simeone D.M., Lubman DM N-linked glycosyl-ation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res. 2007; 6:1126-38.
18. Nishimura S. Toward automated glycan analysis. Adv Carbohydr Chem Biochem. 2011; 65:219-71.
19. Miura Y, Hato M, Shinohara Y., Kuramoto H, Furukawa J, Ku-rogochi M, et al. BlotGlycoABCTM, an integrated glycoblotting technique for rapid and large scale clinical glycomics. Mol Cell Proteomics. 2008; 7:307-7.
20. Nakano M, Nakagawa T, Ito T., Kitada T, Hijioka T, Kasahara A., et al. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer. 2008; 122:2301-9.
21. Alley WR J.r., Vasseur JA, Goetz J.A., Svoboda M., Mann BF, Matei DE, et al N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res. 2012; 11:2282-300.
22. Kodar K, Stadlmann J, Klaamas K., Sergeyev B, Kurtenkov O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J. 2012; 29:57-66.
23. Ding N, Nie H, Sun X., Sun W, Qu Y, Liu X., et al. Human serum N-glycan profiles are age and sex dependent. Age Ageing. 2011; 40:568-75.